Insulin Market Heats Up as Biosimilars and Newer Forms Emerge

Insulin Market Heats Up as Biosimilars and Newer Forms Emerge

August 19, 2014 – It remains to be seen if biosimilars can contribute to better patient care. They could, on the one hand, add to the confusion of doctors and patients, but on the other hand facilitate insulin access for some patients. For industry’s part, it is hoping for lucrative business: earlier this year, Merck also announced its intention to bring a glargine biosimilar to market. “The race is on,” said Dr. Marcus Hompesch, ProSciento CEO. And many are trying to keep the pace.
Read the full article at Medscape.com ยป (This website requires a free registration to view its content.)